Timothy Lu
@timlu
Followers
5K
Following
142
Media
9
Statuses
332
Synthetic Biologist | Biotech Entrepreneur | MIT Professor
Joined April 2007
Excited to share updates on Senti Bio’s SENTI-202 program with Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML. Come join us at 830 AM ET webinar! $SNTI
investors.sentibio.com
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D)...
2
1
9
RT @SentiBio: #MarkYourCalendars: $SNTI leadership will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical da….
0
4
0
Excited to share the latest clinical and preclinical data on our Logic Gated SENTI-202 product at the upcoming AACR meeting!.
Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025 . .@AACR
0
2
2
Very excited to share details on SENTI-202 clinical trial - 2 of 3 pts achieved MRD negative CR in 1st dose level evaluated with a generally well-tolerated preliminary safety profile. Both patients continue to maintain remission (4+ and 3+ months, respectively). $SNTI.
Today, we announced positive initial clinical data from the Phase 1 trial of SENTI-202, a potential first-in-class, off-the-shelf #CARNK #celltherapy for R/R hematologic malignancies, including #AML. Learn more on our webcast on Dec. 3 at 7:30am ET: $SNTI
0
1
13
Excited to share the detailed data on SENTI-202 with Dr. Stephen Strickland and Dr. Kanya Rajangam. Join us to learn about how our #genecircuits enhanced CAR-NK therapies have the potential to transform the treatment of cancer through Logic Gating. $SNTI.
Join us for a live webcast where Senti management and Dr. Stephen Strickland will discuss the positive initial clinical data from the Phase 1 clinical trial of SENTI-202, a Logic-Gated, selective CD33/FLT3-targeting #CARNK #celltherapy. Access here: $SNTI
1
1
11
RT @amirshanehsaz: We @abscibio are excited to unveil IgDesign™ @NeurIPSConf and present our work at @workshopmlsb @AI4D3 @genbio_workshop!….
0
36
0
Check out how $SNTI's Logic Gates precisely discriminate between cancer cells and healthy cells, allowing us to achieve highly precise cancer therapeutics! #synbio.
At Senti, we envision a world where #cancer patients can access smarter therapies that precisely kill their cancer cells and spare their healthy cells. Watch to learn how we're utilizing our proprietary Logic Gating technology to design #CARNK cell therapies to achieve this goal.
1
1
10
Exciting times for @SentiBio as we gain extra fuel to power our Gene Circuit enhanced cell therapies to patients.
Today, we announced that Celadon Partners will acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies. Learn more:
1
2
24
Really excited to publish this work with Maria Eugenia Inda, Gio Traverso, Rabia Yazicigil, and other colleagues advancing a miniaturized pill with living cells for sense-and-respond in vivo!.
Nature research paper: Sub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ
0
10
48
Congratulations to the @openprotein team and @tbepler1 on this exciting new publication. Opportunities for ML-driven protein design continue to grow!.
Excited to announce PoET, our (@timt1630, @tbepler1) retrieval-augmented generative protein language model that achieves state-of-the-art unsupervised variant function prediction performance on #ProteinGym. #MachineLearning #ProteinML 1/9.
1
0
9
Looking forward to speaking today at the JMP Securities Life Science Conference at 230 ET. Join the webcast to learn more about our mission to advance next-gen cell and gene therapies using our gene-circuit platform: #biotech #celltherapy @SentiBio $SNTI.
investors.sentibio.com
The Investor Relations website contains information about Senti Biosciences, Inc.'s business for stockholders, potential investors, and financial analysts.
0
1
12
Also with @BlueRockTx @Bayer, we leveraged our massively parallel promoter design platform to create cell-state-specific synthetic promoters as Smart Sensors to control macrophage polarization (4/5).
1
0
1
In collaboration with @BlueRockTx @Bayer, we have designed pharmacologically relevant, FDA-approved small-molecule-regulated gene circuits for therapeutic applications in the brain, allowing "remote control" of therapies for neuro diseases (3/5).
1
0
0